Quantcast
Last updated on April 16, 2014 at 5:31 EDT

Latest Mucositis Stories

2012-06-08 23:02:32

Synedgen Reports Promising Radiation Treatment Data Claremont, CA (PRWEB) June 08, 2012 Federal agencies are highly concerned about potential dangers to the US population by radiation exposures such as the nuclear incident in Japan or the threat of a terrorist dirty bomb. Synedgen has already demonstrated success in reducing severe oral ulcerations and inflammation in a model of radiation-induced oral mucositis and reducing damage and inflammation in the GI tract after chemical or bacterial...

2012-05-22 10:24:09

LEXINGTON, Mass., May 22, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company was awarded U.S. Patent 8,182,818, entitled "Methods of Using Anti-TNF Antibodies for Treating Radiation Damage to the Digestive Tract." This patent provides broad coverage for using topically administered anti-TNF antibodies to treat radiation induced damage to the...

2012-05-17 02:26:08

DALLAS and NEW YORK, May 17, 2012 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, will host an investor call to update investors on MuGard commercialization activities, including progress with pharmacy benefit managers, payers and pharmacy formularies, and other new developments within the program. The investor conference call is...

2012-04-17 02:29:19

DALLAS and NEW YORK, April 17, 2012 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and oncology supportive care, announced interim results from its ongoing MuGard Phase 4 clinical trial in oral mucositis. An interim analysis from the first forty (40) patients enrolled in the trial showed that patients using MuGard experienced a...

2012-04-04 02:30:02

DALLAS and NEW YORK, April 4, 2012 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that Memorial Sloan-Kettering Cancer Center (MSKCC) has added MuGard to its cancer supportive care pharmacy formulary. Patients undergoing cancer treatment will now have direct access to MuGard from the first day of...

2012-03-26 02:25:55

DALLAS and NEW YORK, March 26, 2012 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, will host an investor call to update investors on fourth quarter results, MuGard commercialization activities, including progress with pharmacy benefit managers, payers and pharmacy formularies, and other new developments within the...

2012-03-06 07:30:00

DALLAS and NEW YORK, March 6, 2012 /PRNewswire/ -- Access Pharmaceuticals, Inc. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and cancer supportive care, updated its lead product website, www.MuGard.com, with a new product testimonial video. To view the testimonial, visit the Testimonials section of the MuGard site or click on the following link: http://www.mugard.com/testimonials/. Conference...

2012-03-05 07:30:00

DALLAS and NEW YORK, March 5, 2012 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and cancer supportive care,announced preliminary revenue results for fourth quarter 2011 and full year 2011. Fourth quarter MuGard product sales increased 400% over third quarter product sales. Full year 2011 revenues, including license revenues, royalties and...

2012-02-22 07:30:00

DALLAS and NEW YORK, Feb. 22, 2012 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that the Company will present at the Cowen and Company 32(nd) Annual Health Care Conference, at The Boston Marriott Copley Place in Boston, MA, March 5-7, 2012. The presentation is scheduled to take place on Wednesday, March 7th at...

2012-02-16 07:30:00

DALLAS and NEW YORK, Feb. 16, 2012 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that Children's Hospital of Colorado has added MuGard to its hospital pharmacy formulary. Children and young adults undergoing cancer treatment will now have direct access to MuGard from the first day of cancer treatment to manage...